Dyadic International, Inc.

Contributing Author

Recent Articles by Dyadic International, Inc.

May-28	Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development DYAI -6.57% GlobeNewswire
May-19	Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference DYAI GlobeNewswire
May-13	Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress DYAI GlobeNewswire
Apr-29	Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026 DYAI -6.47% GlobeNewswire
Mar-25	Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress DYAI -19.63% DYAI GlobeNewswire
Mar-16	Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices DYAI +6.50% GlobeNewswire
Mar-11	Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026 DYAI GlobeNewswire
Mar-04	Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free) DYAI GlobeNewswire
Mar-02	Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone DYAI GlobeNewswire
Feb-17	Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin DYAI GlobeNewswire
Dec-17	Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets DYAI GlobeNewswire
Dec-15	Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins DYAI -9.25% GlobeNewswire
Dec-01	Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets DYAI GlobeNewswire
Nov-12	Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress DYAI GlobeNewswire
Nov-10	Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics DYAI +6.91% GlobeNewswire
Oct-29	Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025 DYAI GlobeNewswire
Oct-06	Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments DYAI GlobeNewswire
Sep-04	Dyadic to Present at Investor Conferences and BPI East DYAI GlobeNewswire
Aug-13	Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress DYAI GlobeNewswire
Aug-05	Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025 DYAI GlobeNewswire
Jul-31	UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock DYAI -6.19% GlobeNewswire
Jul-31	Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock DYAI -6.19% GlobeNewswire
Jul-30	Dyadic International, Inc. Announces Proposed Public Offering of Common Stock DYAI GlobeNewswire
Jun-02	Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications DYAI GlobeNewswire
May-14	Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress DYAI GlobeNewswire
May-01	Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 DYAI GlobeNewswire

Dyadic International, Inc.

Recent Articles by Dyadic International, Inc.

Upgrade your Finviz experience